10-Q: Cartesian Therapeutics Reports Q3 Loss, Increased R&D

Cartesian Therapeutics reported an increased net loss for the third quarter of 2025, driven by higher research and development expenses, despite a reduced net loss for the nine-month period due to fair value adjustments.

Summary

• Net loss for the three months ended September 30, 2025, was $35.9 million, an increase from $24.2 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $37.7 million, a decrease from $67.2 million for the same period in 2024, primarily due to a gain on the change in fair value of contingent value right liability.
• Total revenue for the three months ended September 30, 2025, was $0.5 million, up from $0.4 million in 2024, mainly from grant revenue.
• Total revenue for the nine months ended September 30, 2025, significantly decreased to $1.9 million from $39.7 million in 2024, largely due to the absence of a $30.0 million development milestone from the Sobi License recognized in 2024 and the termination of the Astellas Agreement.
• Research and development (R&D) expenses increased by 21% to $13.8 million for the three months and by 28% to $43.3 million for the nine months ended September 30, 2025, primarily due to the ongoing Phase 3 AURORA trial for Descartes-08 for MG and increased early-stage program expenses.
• General and administrative (G&A) expenses increased to $7.7 million for the three months and $23.3 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and restricted cash totaled $145.1 million as of September 30, 2025, down from $214.3 million at December 31, 2024.
• Cash used in operating activities for the nine months ended September 30, 2025, was $56.2 million, a substantial increase from $16.7 million in the prior year period.
• Accumulated deficit reached $729.8 million as of September 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to significantly increased operating losses and cash burn, a sharp decline in collaboration revenue, and a growing accumulated deficit. While clinical progress for Descartes-08 is positive and the 9-month net loss decreased due to fair value adjustments, the underlying operational financial health shows deterioration and a clear reliance on future capital raises, which introduces significant risk.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by $29.5 million compared to the prior year, primarily due to a favorable change in the fair value of the contingent value right (CVR) liability.
• The lead product candidate, Descartes-08, demonstrated deep and durable clinical benefit in a Phase 2b trial for myasthenia gravis (MG), with 83% of participants maintaining clinically meaningful improvements at six months and sustained improvements at 12 months.
• Received additional grant funding of $1.5 million from the National Institute of Neurological Disorders and Stroke (NINDS) for RNA-based CAR-T cells to combat autoimmune disorders, with the award period running through May 2026.
• Existing cash, cash equivalents, and restricted cash are believed to be sufficient to fund current planned operations for at least the next 12 months from the date of issuance of the financial statements.

Negatives

• Net loss for the three months ended September 30, 2025, increased by $11.7 million to $35.9 million compared to the same period in 2024.
• Operating loss for the nine months ended September 30, 2025, significantly increased to $64.8 million from $17.2 million in the prior year, indicating higher core operational losses.
• Cash used in operating activities for the nine months ended September 30, 2025, increased substantially to $56.2 million from $16.7 million in the prior year, reflecting increased cash burn.
• Collaboration and license revenue for the nine months ended September 30, 2025, plummeted by 99% to $0.4 million from $39.1 million in 2024, largely due to the termination of the Astellas Agreement and the recognition of a $30.0 million Sobi milestone in the prior year.
• Research and development expenses continue to rise, increasing by $9.5 million for the nine-month period, driven by the ongoing Phase 3 AURORA trial and early-stage programs.
• Accumulated deficit grew to $729.8 million as of September 30, 2025, highlighting a history of significant losses.
• The contingent value right (CVR) liability increased by $1.8 million for the three months ended September 30, 2025, resulting in a $16.9 million expense, primarily due to a decrease in interest rates and the passage of time.

Risks

• Future success is dependent on the ability to develop product candidates and attain and sustain profitable operations, which is highly uncertain.
• Requires substantial additional capital to fund operations and continue executing strategy, with no guarantee of obtaining funding on favorable terms or at all.
• If unable to obtain additional funding, may be forced to significantly curtail, delay, or discontinue research and development programs or be unable to expand operations or capitalize on commercialization.
• Clinical development timelines, probability of success, and development costs can differ materially from expectations, potentially requiring significant additional financial resources and time.
• Dependence on third parties, including contract research organizations (CROs) and contract manufacturing organizations (CMOs), for preclinical studies, clinical trials, and manufacturing.
• Ability to protect and enforce intellectual property rights is crucial for product commercialization.
• Operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.
• The liability associated with the CVR Agreement will be settled solely through cash flows received under the Sobi License and other Gross Proceeds, with no obligation for the company to fund any amount related to this liability.

Future Outlook

Expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances Descartes-08 through Phase 3 development, continues to develop preclinical and clinical-stage product candidates, seeks regulatory approvals, expands its intellectual property portfolio, and hires additional staff. The company anticipates needing additional capital to fund operations and will pursue equity offerings, debt financings, and license/collaboration agreements.

Management Comments

• "In our Phase 2b clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit, with 83% of participants maintaining improvements in MG severity scales considered clinically meaningful by expert consensus at six months and sustained improvements in MG severity scales considered clinically meaningful by expert consensus at 12 months."
• "Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable."
• "We expect to continue to incur significant expenses and operating losses for the foreseeable future."
• "Until we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, and license and collaboration agreements."
• "We may be unable to raise capital when needed or on reasonable terms, if at all, which would force us to delay, limit, reduce or terminate our product development or future commercialization efforts."
• "We believe that our existing cash, cash equivalents, and restricted cash as of September 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements."

Industry Context

Cartesian Therapeutics operates in the highly competitive and capital-intensive biotechnology industry, specifically focusing on clinical-stage cell therapy for autoimmune diseases. Its approach, utilizing non-DNA cell therapies that degrade naturally and can be repeatedly dosed in an outpatient setting without pre-treatment chemotherapy, aims to differentiate it from conventional DNA cell therapies. The company faces significant competition from established pharmaceutical and biotechnology firms, requiring substantial ongoing investment in R&D and a clear path to regulatory approval and commercialization.

Comparison to Industry Standards

• Descartes-08's Phase 2b results in myasthenia gravis (MG), showing 83% of participants maintaining clinically meaningful improvements at six months and sustained improvements at 12 months, are considered durable within the industry, where durability is commonly measured over 26 to 52 weeks.
• The company's cell therapy method, which degrades naturally over time without integrating into genetic material, allows for repeated dosing and outpatient administration without pre-treatment chemotherapy, distinguishing it from many conventional DNA cell therapies in the autoimmune disease space.

Management Changes

Corporate Governance

Related Party Transactions

• In the July 2, 2024, 2024 Private Placement, Dr. Timothy A. Springer (Board member), TAS Partners LLC (affiliate of Dr. Springer), and Dr. Chafen Lu (wife of Dr. Springer) purchased an aggregate of 2,359,500 shares of Series B Preferred Stock and common stock for approximately $47.2 million.
• In the November 13, 2023, 2023 Private Placement, Dr. Timothy A. Springer and TAS Partners LLC purchased 99,140.326 shares of Series A Preferred Stock for $40.0 million during the nine months ended September 30, 2024.
• On March 26, 2024, TAS Partners LLC exercised 65,681 Amended 2019 Warrants for $2.9 million in cash, receiving 65,681 shares of common stock and 1,970,443 CVRs.

Stakeholder Impact

• Shareholders: Experience dilution from past and potential future equity raises, and face risks associated with significant operating losses and the need for additional financing. The CVRs provide potential future payouts from legacy assets, but these are subject to deductions and are not guaranteed.
• Employees: Headcount growth in R&D indicates continued investment in personnel, but the separation of the former CTO and past restructuring (90% headcount reduction in April 2023) highlight potential employment volatility.
• Customers (future): Potential for new cell therapies for autoimmune diseases, particularly for myasthenia gravis, if Descartes-08 successfully completes trials and gains regulatory approval.
• Creditors: The company's significant accumulated deficit and ongoing losses may pose risks, though current cash runway is estimated for 12 months.
• Suppliers/Partners: Continued R&D activities and manufacturing operations indicate ongoing engagement with contract research and manufacturing organizations.

Next Steps

• Continue to advance Descartes-08 for Myasthenia Gravis (MG) through Phase 3 development.
• Continue to develop preclinical and clinical-stage product candidates.
• Seek regulatory approvals for any product candidates that successfully complete clinical trials.
• Maintain, expand, and protect the intellectual property portfolio, including through licensing arrangements.
• Hire additional staff, including clinical, scientific, and management personnel.
• Pursue additional cash resources through public or private equity or debt financings or by establishing collaborations with other companies.

Key Dates

Recommendation

While Cartesian Therapeutics shows promising clinical data for Descartes-08 in Phase 2b for myasthenia gravis and has a projected cash runway for the next 12 months, the financial results for the three and nine months ended September 30, 2025, reveal a significant increase in operating losses and cash burn. The substantial decline in collaboration revenue and the growing accumulated deficit highlight the company's early stage and high capital requirements. A 'hold' recommendation is appropriate for seasoned investors who recognize the high-risk, high-reward nature of clinical-stage biotech. They would likely await further clarity on Phase 3 trial progress, successful execution of future financing, and a more sustainable operational cash flow before making a more definitive investment decision. The CVRs offer a potential upside from legacy assets, but this is separate from the core business's operational performance.

Keywords

Cell Therapy, Autoimmune Diseases, Myasthenia Gravis, Descartes-08, Clinical Stage, Biotechnology, SEC Filing, 10-Q, Financial Results, Research and Development, CAR-T, Contingent Value Right, Sobi License, Nasdaq